Compass Pathways Plc (CMPS)
NASDAQ:CMPS
Want to see CMPS full AI Analyst Report?
CMPS Stock Chart & Stats
$6.66
-$0.42(-9.17%)
At close: 4:00 PM EST
$6.66
-$0.42(-9.17%)
Day’s Range― - ―
52-Week Range$2.25 - $10.21
Previous CloseN/A
Volume477.34K
Average Volume (3M)2.22M
Market Cap
$865.73M
Enterprise Value$751.16M
Total Cash (Recent Filing)$149.61M
Total Debt (Recent Filing)$35.03M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
May 07, 2026EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.05
Shares Outstanding134,923,300
10 Day Avg. Volume2,381,107
30 Day Avg. Volume2,222,570
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-12.21
Price to Sales (P/S)0.00
P/FCF Ratio-4.10
Enterprise Value/Market Cap0.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-125.38K
Enterprise Value/Ebitda-3.18
Forecast
1Y Price Target
$21.54Price Target Upside223.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-1.8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Durable Efficacy And DosingAnalyst highlights durable symptom improvement and a deeper response after a second dose, indicating a low-frequency treatment model that differentiates the therapy from chronic maintenance options.
Financing And Cash RunwayAnalyst observes recent financings and warrant exercises materially strengthened the balance sheet and extended cash runway, supporting completion of regulatory filings and commercial preparations.
Regulatory ProgressAnalyst notes Phase 3 trials met primary endpoints and a rolling new-drug application is being finalized with one dataset remaining, strengthening the pathway toward FDA approval.
Bears Say
Commercial ScalabilityAnalyst warns the lengthy inpatient treatment and monitoring requirements may be difficult for clinics to scale, which could limit commercial adoption.
Financial StrainAnalyst highlights substantial operating losses and rising research and general expenses, which could strain financial resources and increase the need for further funding before sustained commercialization.
Trial Signal AmbiguityAnalyst cautions that smaller effect sizes versus earlier studies and activity in the low-dose control could complicate efficacy interpretation and heighten regulatory scrutiny.
COMPASS Pathways News
CMPS FAQ
What was Compass Pathways Plc’s price range in the past 12 months?
Compass Pathways Plc lowest stock price was $2.25 and its highest was $10.21 in the past 12 months.
What is Compass Pathways Plc’s market cap?
Compass Pathways Plc’s market cap is $865.73M.
When is Compass Pathways Plc’s upcoming earnings report date?
Compass Pathways Plc’s upcoming earnings report date is May 07, 2026 which is in 3 days.
How were Compass Pathways Plc’s earnings last quarter?
Compass Pathways Plc released its earnings results on Mar 24, 2026. The company reported -$1 earnings per share for the quarter, missing the consensus estimate of -$0.403 by -$0.597.
Is Compass Pathways Plc overvalued?
According to Wall Street analysts Compass Pathways Plc’s price is currently Undervalued.
Does Compass Pathways Plc pay dividends?
Compass Pathways Plc does not currently pay dividends.
What is Compass Pathways Plc’s EPS estimate?
Compass Pathways Plc’s EPS estimate is -0.44.
How many shares outstanding does Compass Pathways Plc have?
Compass Pathways Plc has 134,923,300 shares outstanding.
What happened to Compass Pathways Plc’s price movement after its last earnings report?
Compass Pathways Plc reported an EPS of -$1 in its last earnings report, missing expectations of -$0.403. Following the earnings report the stock price went down -2.247%.
Which hedge fund is a major shareholder of Compass Pathways Plc?
Currently, no hedge funds are holding shares in CMPS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
COMPASS Pathways Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.54 (223.40% Upside)
$21.54 (223.40% Upside)
Blogger Sentiment
Neutral
CMPS Sentiment 75%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 56.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 17.3%
Last 30 Days ▲ 17.3%
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Negative
20 days / 200 days
Momentum
112.77%
12-Months-Change
Fundamentals
Return on Equity
-335.93%
Trailing 12-Months
Asset Growth
-1.55%
Trailing 12-Months
Company Description
Compass Pathways Plc
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
CMPS Stock 12 Month Forecast
Average Price Target
$21.54
▲(223.40% Upside)
Technical Analysis
Cross Country Healthcare
―
Oncology Institute
―
Talkspace
―
InnovAge Holding
―
Agilon Health
―
Ownership Overview
0.42% Insiders
1.09% Mutual Funds
1.10% Other Institutional Investors
93.67% Public Companies and Individual Investors